Tranzactioneaza Attovia Therapeutics, Inc (US.ATTO) - 22.21 USD (%) Tranzactioneaza
Indici
Descriere companie
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, developing biotherapeutics for immune-mediated diseases in the United States. Its work is built around ATTOBODY, a proprietary biparatopic biologics platform. The pipeline comprises ATTO-1310, an Fc-fusion protein inhibiting IL-31 and aimed at chronic pruritic conditions including chronic pruritus of unknown origin, high-itch atopic dermatitis, cholestatic pruritus and chronic kidney disease-associated pruritus; ATTO-2306, a half-life-extended IgG-fusion protein targeting both IL-13 and IL-31 for atopic dermatitis and other immune-mediated skin diseases such as chronic spontaneous urticaria and prurigo nodularis; and ATTO-1091, a trispecific Fc-fusion protein inhibiting TL1A, IL-23 and integrin α4β7, developed for inflammatory bowel disease, which encompasses ulcerative colitis and Crohn's disease. The company was incorporated in 2022.